
Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder
When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of clinical readouts in blood disorders it is expecting as the impetus.
Now, it’s outlining the first of those data — with an open-label Phase II trial providing what it calls the first clinical evidence supporting its lead candidate in a rare disease that makes patients extra-sensitive to sunlight, resulting in extreme pain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.